Long-term efficacy and predictors of remission following adalimumab treatment in peripheral spondyloarthritis: 3-year results from ABILITY-2

OBJECTIVES: Describe efficacy and safety of 3 years of adalimumab treatment in patients with peripheral spondyloarthritis (pSpA) and identify predictors of remission. METHODS: Patients with pSpA were randomised to adalimumab 40 mg every other week or placebo for 12 weeks; a 144-week open-label exten...

Descripción completa

Detalles Bibliográficos
Autores principales: Van den Bosch, Filip, Mease, Philip J, Sieper, Joachim, Baeten, Dominique L, Xia, Yinglin, Chen, Su, Pangan, Aileen L, Song, In-Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Spondyloarthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5845429/
https://www.ncbi.nlm.nih.gov/pubmed/29531780
http://dx.doi.org/10.1136/rmdopen-2017-000566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5845429/
https://www.ncbi.nlm.nih.gov/pubmed/29531780
http://dx.doi.org/10.1136/rmdopen-2017-000566

Ejemplares similares